These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35805924)

  • 61. Contemporary management of depression.
    Andrews JM; Nemeroff CB
    Am J Med; 1994 Dec; 97(6A):24S-32S. PubMed ID: 7992823
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Antidepressant and tolerance: Determinants and management of major side effects].
    David DJ; Gourion D
    Encephale; 2016 Dec; 42(6):553-561. PubMed ID: 27423475
    [TBL] [Abstract][Full Text] [Related]  

  • 63. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats.
    Wang Y; Cui XL; Liu YF; Gao F; Wei D; Li XW; Wang HN; Tan QR; Jiang W
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1831-5. PubMed ID: 21791234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test.
    Rénéric JP; Lucki I
    Psychopharmacology (Berl); 1998 Mar; 136(2):190-7. PubMed ID: 9551776
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Norepinephrine involvement in antidepressant action.
    Frazer A
    J Clin Psychiatry; 2000; 61 Suppl 10():25-30. PubMed ID: 10910014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Temporal trends of antidepressant utilization patterns in children and adolescents in Hong Kong: A 14-year population-based study with joinpoint regression analysis.
    Lo HKY; Tong CCHY; Chan JKN; Kam CTK; Wong CSM; Cheng CPW; Ho C; Leung BMH; Wong WSH; Yu ZHS; Chang WC
    J Affect Disord; 2024 Jan; 344():61-68. PubMed ID: 37827253
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.
    Pilar-Cuéllar F; Vidal R; Pazos A
    Br J Pharmacol; 2012 Feb; 165(4b):1046-57. PubMed ID: 21627639
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats.
    Nasrallah HA; Hopkins T; Pixley SK
    Brain Res; 2010 Oct; 1354():23-9. PubMed ID: 20682307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fluoxetine effects on behavior and adult hippocampal neurogenesis in female C57BL/6J mice across the estrous cycle.
    Yohn CN; Shifman S; Garino A; Diethorn E; Bokka L; Ashamalla SA; Samuels BA
    Psychopharmacology (Berl); 2020 May; 237(5):1281-1290. PubMed ID: 31965254
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Maternal fluoxetine reduces hippocampal inflammation and neurogenesis in adult offspring with sex-specific effects of periadolescent oxytocin.
    Qiu W; Go KA; Wen Y; Duarte-Guterman P; Eid RS; Galea LAM
    Brain Behav Immun; 2021 Oct; 97():394-409. PubMed ID: 34174336
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Future directions for serotonin and antidepressants.
    Artigas F
    ACS Chem Neurosci; 2013 Jan; 4(1):5-8. PubMed ID: 23336036
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments.
    Haddjeri N; Szabo ST; de Montigny C; Blier P
    Neuropsychopharmacology; 2000 Apr; 22(4):346-56. PubMed ID: 10700654
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discriminative stimulus properties of antidepressant agents: a review.
    Dekeyne A; Millan MJ
    Behav Pharmacol; 2003 Sep; 14(5-6):391-407. PubMed ID: 14501253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment.
    Cryan JF; Page ME; Lucki I
    Psychopharmacology (Berl); 2005 Nov; 182(3):335-44. PubMed ID: 16001105
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.